MG
VYGR icon

Michael Gelband’s Voyager Therapeutics VYGR Stock Holding History

Michael Gelband’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-65,830
Closed -$373K – 2045
2024
Q4 		$373K Buy
65,830
+32,834
+100% +$212K ﹤0.01% 1225
2024
Q3 		$193K Buy
+32,996
New +$240K ﹤0.01% 1459
2023
Q3 		– Sell
-24,321
Closed -$278K – 2189
2023
Q2 		$278K Buy
+24,321
New +$252K ﹤0.01% 1571
2022
Q3 		– Sell
-10,787
Closed -$64K – 2341
2022
Q2 		$64K Sell
10,787
-4,803
-31% -$32.4K ﹤0.01% 1782
2022
Q1 		$119K Buy
+15,590
New +$69.5K ﹤0.01% 1985
2021
Q3 		– Sell
-35,328
Closed -$146K – 2687
2021
Q2 		$146K Buy
+35,328
New +$160K ﹤0.01% 2066
2021
Q1 		– Sell
-12,205
Closed -$87K – 2657
2020
Q4 		$87K Sell
12,205
-7,351
-38% -$70.7K ﹤0.01% 1846
2020
Q3 		$209K Sell
19,556
-22,160
-53% -$260K ﹤0.01% 1455
2020
Q2 		$526K Buy
+41,716
New +$485K 0.01% 1061
2020
Q1 		– Sell
-11,100
Closed -$155K – 1683
2019
Q4 		$155K Buy
+11,100
New +$161K ﹤0.01% 1382

Other funds holding VYGR

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's VYGR Position: Q1 2025 in Review

Michael Gelband sold out of Voyager Therapeutics (VYGR) in Q1 2025, closing a stake of 65,830 shares — an estimated $373K sold.

Michael Gelband first reported a position in VYGR in Q4 2019 and held it in 10 quarters. The position peaked at $526K in Q2 2020. 116 funds tracked by Wall St. Rank hold VYGR as of Q1 2025.

  • Michael Gelband reported no remaining Voyager Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Michael Gelband sold 65,830 Voyager Therapeutics shares in Q1 2025, an estimated $373K.
  • Michael Gelband first reported a position in Voyager Therapeutics in Q4 2019 and held it in 10 quarters.
  • Michael Gelband's Voyager Therapeutics position peaked at $526K in Q2 2020.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2025.

Based on ExodusPoint Capital Management's 13F filing for Q1 2025, filed 14 May 2025.